Cryptosporidiosis Pipeline Review: H1 2018 - Covering Key Players AbbVie, ioGenetics, Novartis and Romark Laboratories - ResearchAndMarkets.com

DUBLIN--()--The "Cryptosporidiosis - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Cryptosporidiosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The pipeline guide also reviews key players involved in therapeutic development for Cryptosporidiosis and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Preclinical stages are 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Companies Mentioned

  • AbbVie Inc
  • ioGenetics Inc
  • Novartis AG
  • Romark Laboratories LC

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. Cryptosporidiosis - Overview
  4. Cryptosporidiosis - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Pipeline by Universities/Institutes
  8. Products under Development by Companies
  9. Products under Development by Universities/Institutes
  10. Cryptosporidiosis - Therapeutics Assessment
  11. Assessment by Target
  12. Assessment by Mechanism of Action
  13. Assessment by Route of Administration
  14. Assessment by Molecule Type
  15. Cryptosporidiosis - Companies Involved in Therapeutics Development
  16. AbbVie Inc
  17. ioGenetics Inc
  18. Novartis AG
  19. Romark Laboratories LC
  20. Cryptosporidiosis - Drug Profiles
  21. Cryptosporidiosis - Dormant Projects
  22. Cryptosporidiosis - Discontinued Products
  23. Cryptosporidiosis - Product Development Milestones
  24. Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/d4t6z5/cryptosporidiosis?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs